KDR and renal cell adenocarcinoma: Currently, systemic targeted treatment is only approved and applied in advanced/metastatic RCC, as there is no evidence up to now for beneficial treatment (with VEGFR-TKIs) in the (neo-)adjuvant setting in localized and locally advanced RCC [83,84,85,86].